myeloma

(redirected from plasma cell myeloma)
Also found in: Thesaurus, Medical, Encyclopedia.

my·e·lo·ma

 (mī′ə-lō′mə)
n. pl. my·e·lo·mas or my·e·lo·ma·ta (-mə-tə)
A malignant tumor formed by the cells of the bone marrow.

my′e·lo′ma·toid′ (-toid′) adj.

myeloma

(ˌmaɪɪˈləʊmə)
n, pl -mas or -mata (-mətə)
(Pathology) a usually malignant tumour of the bone marrow or composed of cells normally found in bone marrow
ˌmyeˈlomaˌtoid adj

my•e•lo•ma

(ˌmaɪ əˈloʊ mə)

n., pl. -mas, -ma•ta (-mə tə)
a tumor of plasma cells, arising in bone marrow and often occurring at multiple sites.
[1855–60]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.myeloma - a tumor of the bone marrow (usually malignant) composed of cells normally found in bone marrow
malignant neoplasm, malignant tumor, metastatic tumor - a tumor that is malignant and tends to spread to other parts of the body
multiple myeloma - myeloma that develops in several places at the same time
Translations

my·e·lo·ma

n. mieloma.
1. cualquier tumor de la médula espinal u ósea;
2. tumor formado por el tipo de células que se encuentran en la médula ósea;
multiple ______ múltiple.

myeloma

n mieloma m; multiple — mieloma múltiple
References in periodicals archive ?
In July 2013 daratumumab was granted Orphan Drug Status by the EMA for the treatment of plasma cell myeloma.
Pathology showed plasma cell myeloma with involvement of the testicular parenchyma, tunica albuginea and spermatic cord.
Plasma cell myeloma (PCM) is the most common type of plasma cell neoplasm (PCN), diagnosed in approximately 20 000 patients each year in the United States.
0 g/dL as major criteria for diagnosis of plasma cell myeloma.
Histologic examination alone is insufficient to discriminate plasma cell granuloma from plasmacytoma or plasma cell myeloma, even though it rarely manifests in the thyroid.
Franchi F, Seminara P, Teodori L, et al: The non-producer plasma cell myeloma.
Plasma cell myeloma (PCM) (or multiple myeloma) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) are both common hematologic neoplasms, each constituting about 10% to 11% of all hematologic malignancies.
Daratumumab was granted Orphan Drug Status by the European Medicines Agency in July 2013 for the treatment of plasma cell myeloma.

Full browser ?